Mortality rate, life expectancy, survival, and the impact of comorbidities on them in people with Parkinson's disease (PD) need to be assessed in settings with different sociodemographic backgrounds. We investigated mortality features in Iranian PD patients focusing on the role of cardiovascular multimorbidity on their survival. Data on mortality and comorbidity profile was gathered in a cohort of 190 individuals with idiopathic PD referred to a Movement Disorders Clinic. Standardized mortality ratio (SMR) compared to the Tehran general population was 3.44 and the life expectancy at birth was 67.4 (95 CI: 59.1-75.8) yr. Patients with at least one cardiovascular comorbidity had a shorter survival time after PD onset (14.0 versus 29.2 yr, p =...
Objective: To evaluate whether the survival of patients with Parkinson disease (PD) is shorter than ...
Parkinson’s disease (PD) is associated with increased mortality despite many advances in treatment. ...
Introduction: Disease interactions can alter functional decline near the end of life (EOL). Parkinso...
Mortality rate, life expectancy, survival, and the impact of comorbidities on them in people with Pa...
Background: previous studies on mortality of Parkinson's disease (PD) enrolled a relatively small nu...
Background. Prognosis of PD is variable. Most studies show higher mortality rates in PD patients com...
Background: Individuals with Parkinson's disease (PD) may have an increased risk of overall mortalit...
BACKGROUND: Parkinson's disease (PD) is associated with increased mortality, but little is known abo...
Background: Individuals with Parkinson's disease (PD) may have an increased risk of overall mortalit...
Objective Few studies have followed Parkinson’s disease (PD) patients from the time of diagnosis to ...
BACKGROUND: Earlier research showed that Parkinson's disease is related to increased overall mortali...
Identification of factors predicting and driving mortality in PD is important for patient informatio...
OBJECTIVE: To determine the life expectancy of patients with Parkinson disease (PD) in the United St...
OBJECTIVE: To examine mortality and associated risk factors, including possible effects of mild cogn...
Objective: To evaluate post-stroke outcomes in patients with Parkinson's disease (PD). Methods: A ma...
Objective: To evaluate whether the survival of patients with Parkinson disease (PD) is shorter than ...
Parkinson’s disease (PD) is associated with increased mortality despite many advances in treatment. ...
Introduction: Disease interactions can alter functional decline near the end of life (EOL). Parkinso...
Mortality rate, life expectancy, survival, and the impact of comorbidities on them in people with Pa...
Background: previous studies on mortality of Parkinson's disease (PD) enrolled a relatively small nu...
Background. Prognosis of PD is variable. Most studies show higher mortality rates in PD patients com...
Background: Individuals with Parkinson's disease (PD) may have an increased risk of overall mortalit...
BACKGROUND: Parkinson's disease (PD) is associated with increased mortality, but little is known abo...
Background: Individuals with Parkinson's disease (PD) may have an increased risk of overall mortalit...
Objective Few studies have followed Parkinson’s disease (PD) patients from the time of diagnosis to ...
BACKGROUND: Earlier research showed that Parkinson's disease is related to increased overall mortali...
Identification of factors predicting and driving mortality in PD is important for patient informatio...
OBJECTIVE: To determine the life expectancy of patients with Parkinson disease (PD) in the United St...
OBJECTIVE: To examine mortality and associated risk factors, including possible effects of mild cogn...
Objective: To evaluate post-stroke outcomes in patients with Parkinson's disease (PD). Methods: A ma...
Objective: To evaluate whether the survival of patients with Parkinson disease (PD) is shorter than ...
Parkinson’s disease (PD) is associated with increased mortality despite many advances in treatment. ...
Introduction: Disease interactions can alter functional decline near the end of life (EOL). Parkinso...